Official Title
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Brief Summary

Expanded access for patients with cancer with RET activation who are ineligible for an ongoing selpercatinib (also known as LOXO-292) clinical trial or have other considerations that prevent access to selpercatinib through an existing clinical trial.

Detailed Description

N/A for expanded access

Available
Individual Patients
Treatment IND/Protocol
Non Small Cell Lung Cancer
Medullary Thyroid Cancer
Colon Cancer
Breast Cancer
Pancreatic Cancer
Papillary Thyroid Cancer
Other Solid Tumors With Evidence of Activating RET Alteration

Drug: Selpercatinib
Open-label expanded access
Other Name: LOXO-292

Eligibility Criteria

Inclusion Criteria:

- Diagnosis of cancer with RET activation, who are not eligible for an ongoing selpercatinib clinical trial and are medically suitable for treatment with selpercatinib

Exclusion Criteria:

- Currently enrolled in an ongoing clinical study of selpercatinib or another RET inhibitor

Eligibility Gender
All
Countries
Australia
Germany
Hong Kong
Israel
Singapore
Spain
Switzerland
United States
Locations

Cancer Treatment Centers of America
Goodyear, Arizona, 85338

Available

Investigator: Ashish Sangal, MD

Investigator: Ashish Sangal, MD

Mayo Clinic Hospital
Scottsdale, Arizona, 85054

Available

Investigator: Nina Karlin

Investigator: Nina Karlin, MD

City of Hope
Duarte, California, 91010

Available

Investigator: Erminia Massarelli, MD, PhD

Investigator: Erminia Massarelli, MD, PhD

UC San Diego Moores Cancer Center
La Jolla, California, 92093

Available

Investigator: Lyudmila Bazhenova, MD

Investigator: Lyudmia Bazhenova, MD

UCI Health - Chao Family Comprehensive Cancer Center
Orange, California, 92868

Available

Investigator: Viola Zhu, MD

Investigator: Viola Zhu, MD

UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, 94158

Available

Investigator: Alain Algazi, MD

Investigator: Alain Algazi, MD

Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center
Torrance, California, 90502

Available

Investigator: Mykola Onyshchenko, MD

Investigator: Mykola Onshchenko, MD

Kaiser Permanente Medical Center
Vallejo, California, 94589

Available

Investigator: Jennifer Suga, MD

Investigator: Jennifer Suga, MD

Memorial Regional Hospital
Hollywood, Florida, 33021

Available

Investigator: Luis Raez, MD

Investigator: Luis Raez, MD

Mayo Clinic Hospital
Jacksonville, Florida, 32224

Available

Investigator: Victor Bernet, MD

Investigator: Victor Bernet, MD

AdventHealth Orlando
Orlando, Florida, 32804

Available

Investigator: Mark Socinski, MD

Investigator: Mark Socinski, MD

Tallahassee Memorial Hospital
Tallahassee, Florida, 32308

Available

Investigator: Karen Russell, MD

Investigator: Karen Russell, MD

University Cancer and Blood Center
Athens, Georgia, 30607

Available

Investigator: Petros Nikolinakos, MD

Investigator: Petros Nikolinakos, MD

Emory University
Atlanta, Georgia, 30322

Available

Investigator: Taofeek Owonikoko, MD

Investigator: Taofeek Owonikoko, MD

Cancer Treatment Centers of America, Chicago
Chicago, Illinois, 60099

Available

Investigator: Eugene Ahn, MD

Investigator: Eugene Ahn, MD

University of Chicago Medical Center
Chicago, Illinois, 60637

Available

Investigator: Christine Bestvina, MD

Investigator: Christine Bestvina, MD

Massachusetts General Hospital
Boston, Massachusetts, 02114

Available

Investigator: Lori Wirth, MD

Investigator: Lori Wirth, MD

Dana-Farber Cancer Institute
Boston, Massachusetts, 02215

Available

Investigator: Geoffrey Oxnard, MD

Investigator: Geoffrey Oxnard, MD

University of Michigan
Ann Arbor, Michigan, 48109

Available

Investigator: Francis Worden, MD

Investigator: Francis Worden, MD

START Midwest
Grand Rapids, Michigan, 49546

Available

Investigator: Nehal Lakhani, MD

Investigator: Nehal Lakhani, MD

Mayo Clinic Hospital
Rochester, Minnesota, 55905

Available

Investigator: John Morris, MD

Investigator: John Morris, MD

Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, 89169

Available

Investigator: Fadi Braiteh, MD

Investigator: Fadi Braiteh, MD

Memorial Sloan Kettering Cancer Center
New York, New York, 10065

Available

Investigator: Alexander Drilon, MD

Investigator: Alexander Drilon, MD

Cleveland Clinic
Cleveland, Ohio, 44195

Available

Investigator: Nathan Pennell, MD

Investigator: Nathan Pennell, MD

JamesCare at Martha Morehouse Medical Plaza
Columbus, Ohio, 43210

Available

Investigator: Manisha Shah, MD

Investigator: Manisah Shah, MD

Cancer Treatment Centers of America
Tulsa, Oklahoma, 74133

Available

Investigator: Theodore Pollock, MD

Investigator: Theodore Pollock, MD

University of Pennsylvania, Perelman School of Medicine
Philadelphia, Pennsylvania, 19104

Available

Investigator: Marcia Brose, MD, PhD

Investigator: Marcia Brose, MD, PhD

Cancer Treatment Centers of American, Philadelphia
Philadelphia, Pennsylvania, 19124

Available

Investigator: Arturo Loaiza-Bonilla, MD

Investigator: Arturo Loaiza-Bonilla, MD

M.D. Anderson Cancer Center
Houston, Texas, 77030

Available

Investigator: Vivek Subbiah, MD

Investigator: Vivek Subbiah, MD

Oncology Consultants
Houston, Texas, 77030

Available

Investigator: Julio Peguero, MD

Investigator: Julio Peguero, MD

Virginia Cancer Specialists
Fairfax, Virginia, 22031

Available

Investigator: Alexander Spira, MD

Investigator: Alexander Spira, MD

Contacts

Patient Advocacy
888-406-9574
LoxoNPP@UBC.com

Patient Advocacy
855-RET-4-292 (855-738-4292)
clinicaltrials@loxooncology.com

Jen Kherani, MD
Study Director
Loxo Oncology

Loxo Oncology, Inc.
Eli Lilly and Company
NCT Number
MeSH Terms
Thyroid Neoplasms
Thyroid Cancer, Papillary
Thyroid Diseases